Clinical Trials Logo

Severe Hemophilia A clinical trials

View clinical trials related to Severe Hemophilia A.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT02196207 Withdrawn - Severe Hemophilia A Clinical Trials

Hemophilia Inhibitor Clinical Trials (INHIBIT) Platform

INHIBIT
Start date: August 2020
Phase: Phase 3
Study type: Interventional

This study will evaluate if Eloctate is superior to Emicizumab in reducing inhibitors in children with severe hemophilia when given before the first bleed (preemptive) and continued weekly to prevent bleeds (prophylaxis); and whether Eloctate immune tolerance induction (ITI) plus emicizumab is superior to Eloctate ITI alone in eradicating inhibitor formation in children and adults with severe hemophilia A.

NCT ID: NCT01051544 Withdrawn - Severe Hemophilia A Clinical Trials

Study of First TIME Immunotolerance Induction in Severe Hemophilia A Patients With Inhibitor at High Risk of Failure: Comparison With FVIII Concentrates With or Without Von Willebrand Factor - RES.I.S.T. Naive

RESIST NAIVE
Start date: September 25, 2009
Phase: N/A
Study type: Interventional

This is a prospective, controlled, randomized, open label study, aimed at comparing FVIII/VWF concentrates with FVIII concentrates at 200 IU/kg daily in their ability to induce immune tolerance in Haemophilia A patients with high responding inhibitors and poor prognosis for success.